Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins

Research output: Journal contributionsJournal articlesResearchpeer-review

Standard

Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. / Pavlenko, Maxim ; Roos, Anna-Karin ; Leder, Christoph et al.
In: Cancer Immunology, Immunotherapy , Vol. 53, No. 12, 12.2004, p. 1085-1092.

Research output: Journal contributionsJournal articlesResearchpeer-review

Harvard

APA

Vancouver

Pavlenko M, Roos AK, Leder C, Hansson LO, Kiessling R, Levitskaya E et al. Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunology, Immunotherapy . 2004 Dec;53(12):1085-1092. doi: 10.1007/s00262-004-0559-z

Bibtex

@article{7e14d9a6080f400faabe556a1a2efaed,
title = "Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins",
abstract = "The ability of heat shock proteins (HSPs) to increase the potency of protein- and DNA-based vaccines has been previously reported. We have constructed several plasmid-based vectors encoding chimeric proteins containing prostate-specific antigen (PSA) fused to Mycobacterium tuberculosis hsp70, M. bovis hsp65, Escherichia coli DnaK (hsp70), or human hsp70. Immunizing mice with these plasmids induced CD8+ cytotoxic T lymphocytes (CTLs) specific to human PSA and protected mice from a subsequent subcutaneous challenge with PSA-expressing tumors. We did not observe a significant difference either in the levels of PSA-specific CTLs or in protection against tumor challenge in mice immunized with plasmids expressing PSA-HSP chimeric proteins, as compared to mice receiving a conventional PSA-expressing DNA plasmid. Our data indicate that using HSPs as fusion partners for tumor-specific antigens does not always result in the enhancement of antigen-specific CTL responses when applied in the form of DNA vaccines.",
keywords = "Biology, CTL, DNA vaccine, heat shock protein, prostate-specific antigen",
author = "Maxim Pavlenko and Anna-Karin Roos and Christoph Leder and L.O. Hansson and Rolf Kiessling and Elena Levitskaya and Pavel Pisa",
note = "Funding Information: Acknowledgements We thank Mr W David Culp Jr and Ms Ashley Miller for the critical assistance with preparation of the manuscript. This study was supported by the Cancer Society in Stockholm, the Swedish Cancer Society, Karolinska Institute Funds, Swedish Research Council, Wallenberg{\textquoteright}s Foundation, and Swedish Society for Medical Research.",
year = "2004",
month = dec,
doi = "10.1007/s00262-004-0559-z",
language = "English",
volume = "53",
pages = "1085--1092",
journal = "Cancer Immunology, Immunotherapy ",
issn = "1432-0851",
publisher = "Springer Science and Business Media Deutschland",
number = "12",

}

RIS

TY - JOUR

T1 - Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins

AU - Pavlenko, Maxim

AU - Roos, Anna-Karin

AU - Leder, Christoph

AU - Hansson, L.O.

AU - Kiessling, Rolf

AU - Levitskaya, Elena

AU - Pisa, Pavel

N1 - Funding Information: Acknowledgements We thank Mr W David Culp Jr and Ms Ashley Miller for the critical assistance with preparation of the manuscript. This study was supported by the Cancer Society in Stockholm, the Swedish Cancer Society, Karolinska Institute Funds, Swedish Research Council, Wallenberg’s Foundation, and Swedish Society for Medical Research.

PY - 2004/12

Y1 - 2004/12

N2 - The ability of heat shock proteins (HSPs) to increase the potency of protein- and DNA-based vaccines has been previously reported. We have constructed several plasmid-based vectors encoding chimeric proteins containing prostate-specific antigen (PSA) fused to Mycobacterium tuberculosis hsp70, M. bovis hsp65, Escherichia coli DnaK (hsp70), or human hsp70. Immunizing mice with these plasmids induced CD8+ cytotoxic T lymphocytes (CTLs) specific to human PSA and protected mice from a subsequent subcutaneous challenge with PSA-expressing tumors. We did not observe a significant difference either in the levels of PSA-specific CTLs or in protection against tumor challenge in mice immunized with plasmids expressing PSA-HSP chimeric proteins, as compared to mice receiving a conventional PSA-expressing DNA plasmid. Our data indicate that using HSPs as fusion partners for tumor-specific antigens does not always result in the enhancement of antigen-specific CTL responses when applied in the form of DNA vaccines.

AB - The ability of heat shock proteins (HSPs) to increase the potency of protein- and DNA-based vaccines has been previously reported. We have constructed several plasmid-based vectors encoding chimeric proteins containing prostate-specific antigen (PSA) fused to Mycobacterium tuberculosis hsp70, M. bovis hsp65, Escherichia coli DnaK (hsp70), or human hsp70. Immunizing mice with these plasmids induced CD8+ cytotoxic T lymphocytes (CTLs) specific to human PSA and protected mice from a subsequent subcutaneous challenge with PSA-expressing tumors. We did not observe a significant difference either in the levels of PSA-specific CTLs or in protection against tumor challenge in mice immunized with plasmids expressing PSA-HSP chimeric proteins, as compared to mice receiving a conventional PSA-expressing DNA plasmid. Our data indicate that using HSPs as fusion partners for tumor-specific antigens does not always result in the enhancement of antigen-specific CTL responses when applied in the form of DNA vaccines.

KW - Biology

KW - CTL

KW - DNA vaccine

KW - heat shock protein

KW - prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=8644277992&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/6ef4a9e9-90c2-3136-9988-9e2dd5b1c4fa/

U2 - 10.1007/s00262-004-0559-z

DO - 10.1007/s00262-004-0559-z

M3 - Journal articles

VL - 53

SP - 1085

EP - 1092

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 1432-0851

IS - 12

ER -

Recently viewed

Publications

  1. Ideological Stances in Yoruba Nation Secessionist Discourse in Nigerian Virtual Communities
  2. Shock as a black box 2. Effects of adiabatic deceleration and convection included
  3. The effectiveness of interventions during and after residence in women’s shelters
  4. Globalization’s limits to the environmental state? Integrating telecoupling into global environmental governance
  5. Article 72 CISG
  6. When history matters
  7. Spacing organization: non-representational theory and performing organizational space
  8. Identifying business opportunities for sustainable development
  9. Werbung
  10. Transformative education
  11. Where is cinema (today)?
  12. C.S.ルイス 「ライオンと魔女」の謎を解く―ナルニアガイド
  13. Business Entry and Window of Opportunity
  14. Imagology Meets Children's Literature
  15. Making a difference by marking the difference
  16. How to make universal, voluntary testing for COVID-19 work? A behavioural economics perspective
  17. Intentionalisten vs. Strukturalisten
  18. How do conflicts impact change in family businesses?
  19. Freie Rede
  20. Markenwert
  21. „Why Do Intellectuals Oppose Capitalism?“
  22. Remastering
  23. Conflict strength:
  24. Konzeptionsentwicklung – eine Einführung
  25. "Instrumentalität"
  26. Anchoring and Sleep Inertia
  27. Umweltverträglichkeitsprüfung
  28. Removal of the anti-cancer drug methotrexate from water by advanced oxidation processes
  29. Outcome expectations and work design characteristics in post-retirement work planning
  30. An overview of European programs to support energy projects in Africa and strategies to involve the private sector
  31. Mitarbeitergeleitete engpassorientierte Steuerung
  32. Elections in Asia and the Pacific: a data handbook
  33. What do we know about Antibiotics in the Environment?
  34. Initiative in work teams